ĐÁNH GIÁ KẾT QUẢ HÓA XẠ TRỊ ĐỒNG THỜI TRIỆT CĂN UNG THƯ CỔ TỬ CUNG GIAI ĐOẠN III TẠI BỆNH VIỆN K

Abstract

Objectives: The aims of our study were to evaluate the result of concurrent chemoradiotherapy in FIGO III cervical cancer patients and late toxicities of this treatment method. Patients and Methods: 76 patients stage III cervical cancer (FIGO 2018) with good performance status (PS 0-2) were treated with three-dimensional conformal radiation therapy (3D CRT) combined with chemotherapy (weekly Cisplatin regimen), followed by computed tomography-guided high-dose-rate (HDR) brachytherapy. The primary end point was 3-year disease-free survival rate and prognosis factors, secondary end points were late toxicities of this treatment. Result: The 3-year DFS for the 76 eligible patients was 67.5%. On multivariate analyses, invasion of the lower third of vagina, short axis of pelvic lymph node diameter of ≥ 15mm, para-aortic lymph node metastasis were identified as adverse prognostic factors for DFS in stage III cervical cancer patients. The rates of grade 1-2 and 3-4 of gastrointestinal and genitourinary late toxicities were 44,7%; 18,4%; 9,2% and 2,6% respectively. Conclusion: Concurrent chemoradiotherapy with HDR brachytherapy for patients stage III cervical cancer improved progression-free survival while late toxicities were acceptable for major patients.